Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

venetoclax 30obinutuzumab 22acalabrutinib 20Specimen Handling 19ibrutinib 16Cyclophosphamide 15Biopsy 15pirtobrutinib 14zanubrutinib 12fludarabine 12Rituximab 12Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 5Stem Cell Transplantation 4Blood Component Removal 4ARQ531 4idelalisib 3fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3tocilizumab 2polatuzumab vedotin 2Watchful Waiting 2Sirolimus 2Prednisone 2Pneumococcal Vaccines 2Lisaftoclax 2Leukapheresis 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Lisaftoclax × Clear all
NCT05147467 2026-03-27

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
75 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Ascentage Pharma Group Inc.

Phase 1/2 Recruiting
123 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡